PL3433233T3 - Nowa krystaliczna postać soli 1-(5-(2,4-difluorofenylo)-1-((3-fluorofenylo)sulfonylo)-4-metoksy-1H-pirol-3-ilo)-N-metylometanoaminy - Google Patents

Nowa krystaliczna postać soli 1-(5-(2,4-difluorofenylo)-1-((3-fluorofenylo)sulfonylo)-4-metoksy-1H-pirol-3-ilo)-N-metylometanoaminy

Info

Publication number
PL3433233T3
PL3433233T3 PL17770546T PL17770546T PL3433233T3 PL 3433233 T3 PL3433233 T3 PL 3433233T3 PL 17770546 T PL17770546 T PL 17770546T PL 17770546 T PL17770546 T PL 17770546T PL 3433233 T3 PL3433233 T3 PL 3433233T3
Authority
PL
Poland
Prior art keywords
pyrrol
difluorophenyl
fluorophenyl
sulfonyl
methoxy
Prior art date
Application number
PL17770546T
Other languages
English (en)
Inventor
Aeri Kim
Kwan Hyung Cho
Original Assignee
Daewoong Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59900401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3433233(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daewoong Pharmaceutical Co., Ltd. filed Critical Daewoong Pharmaceutical Co., Ltd.
Publication of PL3433233T3 publication Critical patent/PL3433233T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PL17770546T 2016-03-25 2017-03-17 Nowa krystaliczna postać soli 1-(5-(2,4-difluorofenylo)-1-((3-fluorofenylo)sulfonylo)-4-metoksy-1H-pirol-3-ilo)-N-metylometanoaminy PL3433233T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020160036080A KR102081920B1 (ko) 2016-03-25 2016-03-25 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
EP17770546.4A EP3433233B1 (en) 2016-03-25 2017-03-17 Novel crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine salt
PCT/KR2017/002914 WO2017164576A1 (en) 2016-03-25 2017-03-17 Novel crystalline form of 1-(5-(2,4-difluorophenyl)-l-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine salt

Publications (1)

Publication Number Publication Date
PL3433233T3 true PL3433233T3 (pl) 2020-12-14

Family

ID=59900401

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17770546T PL3433233T3 (pl) 2016-03-25 2017-03-17 Nowa krystaliczna postać soli 1-(5-(2,4-difluorofenylo)-1-((3-fluorofenylo)sulfonylo)-4-metoksy-1H-pirol-3-ilo)-N-metylometanoaminy

Country Status (31)

Country Link
US (6) US10336695B2 (pl)
EP (1) EP3433233B1 (pl)
JP (1) JP6554617B2 (pl)
KR (1) KR102081920B1 (pl)
CN (1) CN108602772B (pl)
AR (1) AR107963A1 (pl)
AU (1) AU2017238918B2 (pl)
BR (1) BR112018069461A2 (pl)
CA (1) CA3014745C (pl)
CL (3) CL2018002416A1 (pl)
CO (1) CO2018008833A2 (pl)
DO (1) DOP2018000190A (pl)
EA (1) EA029995B1 (pl)
ES (1) ES2818902T3 (pl)
HR (1) HRP20201594T1 (pl)
HU (1) HUE053502T2 (pl)
JO (1) JOP20170070B1 (pl)
MA (1) MA43833B1 (pl)
MX (1) MX382701B (pl)
MY (1) MY196299A (pl)
NZ (1) NZ745266A (pl)
PE (1) PE20190170A1 (pl)
PH (1) PH12018501846B1 (pl)
PL (1) PL3433233T3 (pl)
PT (1) PT3433233T (pl)
RS (1) RS60884B1 (pl)
SG (1) SG11201806966SA (pl)
SI (1) SI3433233T1 (pl)
TN (1) TN2018000288A1 (pl)
TW (1) TWI626234B (pl)
WO (1) WO2017164576A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233456B1 (ko) 2017-05-31 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102126576B1 (ko) * 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
PH12022551415A1 (en) * 2019-12-18 2023-11-20 Daewoong Pharmaceutical Co Ltd Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
UA130030C2 (uk) * 2020-12-18 2025-10-15 Тевун Фармасутікал Ко., Лтд. Препарат для перорального введення, який містить 1-(5-(2,4-дифлуорфеніл)-1-((3-флуорфеніл)сульфоніл)-4-метокси-1h-пірол-3-іл)-n-метилметанамін
AU2022280595B2 (en) 2021-05-26 2024-11-14 Daewoong Pharmaceutical Co., Ltd. Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
TWI892291B (zh) * 2021-05-26 2025-08-01 南韓商大熊製藥股份有限公司 含有1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺之液體醫藥組成物之醫藥容器
CN117820193A (zh) * 2022-09-29 2024-04-05 安徽皓元药业有限公司 一种非苏拉赞盐酸盐晶型a及其制备方法
KR102974932B1 (ko) * 2023-07-21 2026-06-09 한림제약(주) 보노프라잔 푸마르산염의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5173192B2 (ja) * 2004-09-30 2013-03-27 武田薬品工業株式会社 プロトンポンプ阻害薬
KR101115857B1 (ko) 2005-08-30 2012-04-12 다케다 야쿠힌 고교 가부시키가이샤 산 분비 억제제로서 1-헤테로시클릴술포닐, 2-아미노메틸,5-(헤테로-) 아릴 치환된 1-ｈ-피롤 유도체
US7994205B2 (en) * 2006-03-31 2011-08-09 Takeda Pharmaceutical Company Limited Aryl-or heteroaryl-sulfonyl compounds as acid secretion inhibitors
WO2008036211A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
US8933105B2 (en) * 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
JP6292736B2 (ja) * 2012-11-19 2018-03-14 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド ピロールスルホンアミド誘導体、その製造法およびその医療用途
KR102084185B1 (ko) * 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
CN104447491B (zh) * 2014-11-19 2017-06-23 连云港恒运医药有限公司 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途
CN106957252B (zh) * 2014-11-19 2019-11-19 连云港恒运药业有限公司 一种质子泵抑制剂中间体及其制备方法
KR101613245B1 (ko) * 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20170113040A (ko) 2016-03-25 2017-10-12 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233456B1 (ko) 2017-05-31 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102233455B1 (ko) 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법

Also Published As

Publication number Publication date
PH12018501846A1 (en) 2019-05-15
HK1254393A1 (zh) 2019-07-19
ES2818902T3 (es) 2021-04-14
DOP2018000190A (es) 2018-09-30
WO2017164576A1 (en) 2017-09-28
WO2017164576A8 (en) 2018-08-09
EA201790454A3 (ru) 2017-11-30
US11459297B2 (en) 2022-10-04
US20190322622A1 (en) 2019-10-24
BR112018069461A2 (pt) 2019-02-12
TN2018000288A1 (en) 2020-01-16
EA201790454A2 (ru) 2017-09-29
HRP20201594T1 (hr) 2020-12-11
MX2018009219A (es) 2018-09-10
US11858894B2 (en) 2024-01-02
US20200181082A1 (en) 2020-06-11
CL2018002416A1 (es) 2018-12-28
PH12018501846B1 (en) 2019-05-15
JOP20170070B1 (ar) 2021-08-17
MX382701B (es) 2025-03-13
RS60884B1 (sr) 2020-11-30
AU2017238918A1 (en) 2018-08-16
AU2017238918A8 (en) 2018-08-30
SG11201806966SA (en) 2018-09-27
JP2019509308A (ja) 2019-04-04
US10683268B2 (en) 2020-06-16
TW201736343A (zh) 2017-10-16
MA43833B1 (fr) 2020-08-31
CA3014745C (en) 2020-04-28
AU2017238918B2 (en) 2019-05-09
US20210139424A1 (en) 2021-05-13
CL2020001826A1 (es) 2020-12-11
US20200123106A1 (en) 2020-04-23
US20230159454A1 (en) 2023-05-25
CO2018008833A2 (es) 2018-09-28
AR107963A1 (es) 2018-07-04
CL2020000186A1 (es) 2020-08-07
KR102081920B1 (ko) 2020-02-26
MY196299A (en) 2023-03-24
US20190047953A1 (en) 2019-02-14
US10336695B2 (en) 2019-07-02
US10913715B2 (en) 2021-02-09
EA029995B1 (ru) 2018-06-29
PE20190170A1 (es) 2019-02-01
HUE053502T2 (hu) 2021-07-28
KR20170111170A (ko) 2017-10-12
CN108602772A (zh) 2018-09-28
EP3433233A1 (en) 2019-01-30
CA3014745A1 (en) 2017-09-28
EP3433233B1 (en) 2020-07-22
CN108602772B (zh) 2021-06-04
TWI626234B (zh) 2018-06-11
JP6554617B2 (ja) 2019-07-31
US10889545B2 (en) 2021-01-12
EP3433233A4 (en) 2019-08-14
NZ745266A (en) 2020-03-27
PT3433233T (pt) 2020-08-03
SI3433233T1 (sl) 2020-10-30

Similar Documents

Publication Publication Date Title
SI3433232T1 (sl) Nova kislinska dodatna sol 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoksi-1H-pirol- 3-IL)-N-metilmetanamina
SI3433233T1 (sl) Nova kristalna oblika soli 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoksi-1H-pirol- 3-IL)-N-metilmetanamina
EP3871673A4 (en) NEW INDAZOLE COMPOUND OR SALT THEREOF
IL247833A0 (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
MX2020005323A (es) Triazol azinas de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
IL275363A (en) Cyclohexylic acid triazole azoles as LPA antagonists
EP3398938A4 (en) PYRAZOL COMPOUND OR SALT AND MANUFACTURING METHOD, HERBICIDAL COMPOSITION AND USE THEREOF
CL2016003145A1 (es) Compuestos de [1,2,4]triazol sustituido
CU20170057A7 (es) Derivados de feniltriazol sustituido con hidroxialquilo
ZA201606386B (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
EP3466934A4 (en) SULPHONAMIDE COMPOUND OR SALT THEREOF
IL271399A (en) Methods for the preparation of heterocyclic 3,1-benzodioxole compounds
EP3480198A4 (en) Novel compound or pharmaceutically acceptable salt of it
IL251777B (en) 5-(3-hydroxy-propyn-1-yl)-3-pyrazol-4-yl)-indole derivatives as nick inhibitors
IL259617B (en) Methods for the preparation of 3,1-benzodioxole heterocyclic compounds
IL249336A0 (en) Methods for the preparation of heterocyclic compounds of 3,1-benzodioxole
IL270789A (en) Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
SI3298008T1 (sl) Kristalinična oblika spojine (S)-3-(4-(5-(2-ciklopentil-6-metoksi-piridin-4-IL)-(1,2,4)oksadiazol-3- IL)-2-etil-6-metil-fenoksi)-propan 1,2-diol
ZA201600021B (en) 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator
SI3143019T1 (sl) Kristalna oblika 6-((4R)-4-metil-1,2-dioksido-1,2,6-tiadiazinan-2-IL)isokvinolin-1- karbonitrila
GR1008554B (el) Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου
EP3816176A4 (en) HYDRATE CRYSTAL FROM 3 ', 3'-CGAMP
HK40029095A (en) Heterocyclic compounds as adenosine antagonists
HK1233637A1 (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation